Who are Etravirine Tablets's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Dolutegravir / Lamivudine Pill, Emtricitabine / Tenofovir Disoproxil Pill, Raltegravir, tenofovir/emtricitabine, TAF/FTC, Tenofovir/Emtricitabine and efavirenz, DOR/3TC/TDF.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/etravirine-tablets.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Etravirine Tablets — Competitive Intelligence Brief

Etravirine Tablets (Etravirine Tablets) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Non-nucleoside reverse transcriptase inhibitor. Area: Infectious Disease.

phase 2 Non-nucleoside reverse transcriptase inhibitor Reverse transcriptase Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Etravirine Tablets (Etravirine Tablets) — IRCCS Eugenio Medea. Non-nucleoside reverse transcriptase inhibitor

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Etravirine Tablets TARGET	Etravirine Tablets	IRCCS Eugenio Medea	phase 2	Non-nucleoside reverse transcriptase inhibitor	Reverse transcriptase
Dolutegravir / Lamivudine Pill	Dolutegravir / Lamivudine Pill	Charlotte-Paige Rolle, MD	marketed	Antiretroviral combination (INSTI + NRTI)	HIV integrase; HIV reverse transcriptase
Emtricitabine / Tenofovir Disoproxil Pill	Emtricitabine / Tenofovir Disoproxil Pill	Fundacion IDEAA	marketed	Nucleoside/nucleotide reverse transcriptase inhibitor combination	HIV-1 reverse transcriptase
Raltegravir, tenofovir/emtricitabine	Raltegravir, tenofovir/emtricitabine	University of California, San Francisco	marketed	Antiretroviral combination therapy (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase
TAF/FTC	TAF/FTC	Göteborg University	marketed	Nucleoside reverse transcriptase inhibitor combination	HIV reverse transcriptase
Tenofovir/Emtricitabine and efavirenz	Tenofovir/Emtricitabine and efavirenz	GlaxoSmithKline	marketed	Antiretroviral combination therapy (NRTI + NNRTI)	HIV reverse transcriptase
DOR/3TC/TDF	DOR/3TC/TDF	Prism Health North Texas	marketed	Antiretroviral combination therapy (NNRTI + NRTI + NtRTI)	HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Non-nucleoside reverse transcriptase inhibitor class)

Laboratoires NEGMA · 2 drugs in this class
IRCCS Eugenio Medea · 1 drug in this class
Merck Sharp & Dohme LLC · 1 drug in this class
The HIV Netherlands Australia Thailand Research Collaboration · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Etravirine Tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/etravirine-tablets. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab